Stay updated on Cladribine & LoDAC vs. HMA & Venetoclax Clinical Trial

Sign up to get notified when there's something new on the Cladribine & LoDAC vs. HMA & Venetoclax Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Cladribine & LoDAC vs. HMA & Venetoclax Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    No Change Detected
  4. Check
    3 days ago
    No Change Detected
  5. Check
    4 days ago
    No Change Detected
  6. Check
    7 days ago
    Change Detected
    Summary
    The value 02 20 has been updated to 05 08 on the webpage, indicating a recent change in the documentation related to a Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction.
    Difference
    0.6%
    Check dated 2024-05-09T01:56:31.000Z thumbnail image
  7. Check
    15 days ago
    Change Detected
    Difference
    3%
    Check dated 2024-04-30T22:31:56.000Z thumbnail image

Stay in the know with updates to Cladribine & LoDAC vs. HMA & Venetoclax Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Cladribine & LoDAC vs. HMA & Venetoclax Clinical Trial page.